Skip to main content
. 2019 Sep 4;14(9):e0221568. doi: 10.1371/journal.pone.0221568

Fig 3.

Fig 3

Resistance selection risk characterisation for (A) macrolides and (B) fluoroquinolones using 2015/16 prescription statistics.